



Supplementary Figure 1. VDR expression by healthy- and MS-derived Th17 and Th17.1 cells. Relative VDR expression by unstimulated Th17 and Th17.1 cells from healthy controls (HC, $n = 5$) and MS patients treated with natalizumab for 12 months (NTZ-MS, $n = 5$). Data were compared using Mann-Whitney U tests.